AcelRx Pharmaceuticals Inc (ACRX) Insider Sells $141,755.00 in Stock

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) insider Badri N. Dasu sold 28,351 shares of the business’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $5.00, for a total transaction of $141,755.00. Following the sale, the insider now owns 54,061 shares of the company’s stock, valued at $270,305. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of ACRX stock opened at $4.15 on Friday. The company has a debt-to-equity ratio of -0.15, a quick ratio of 3.96 and a current ratio of 4.01. AcelRx Pharmaceuticals Inc has a twelve month low of $1.55 and a twelve month high of $5.03.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $0.82 million for the quarter, compared to analyst estimates of $0.93 million. As a group, equities analysts predict that AcelRx Pharmaceuticals Inc will post -0.83 EPS for the current year.

Several research firms have issued reports on ACRX. Zacks Investment Research downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. Oppenheimer reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Monday. Cantor Fitzgerald set a $8.00 price objective on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $10.00 price objective (up from $7.00) on shares of AcelRx Pharmaceuticals in a research note on Wednesday, October 10th. Finally, Jefferies Financial Group upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a research note on Monday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $7.50.

Several hedge funds have recently made changes to their positions in ACRX. GSA Capital Partners LLP purchased a new position in shares of AcelRx Pharmaceuticals in the first quarter valued at $113,000. Lincoln Capital Corp purchased a new position in shares of AcelRx Pharmaceuticals in the second quarter valued at $116,000. Granite Investment Partners LLC purchased a new position in shares of AcelRx Pharmaceuticals in the second quarter valued at $182,000. Northern Trust Corp boosted its stake in shares of AcelRx Pharmaceuticals by 60.8% in the first quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock valued at $192,000 after purchasing an additional 34,584 shares during the period. Finally, FMR LLC boosted its stake in shares of AcelRx Pharmaceuticals by 1,094.6% in the second quarter. FMR LLC now owns 298,644 shares of the specialty pharmaceutical company’s stock valued at $1,008,000 after purchasing an additional 273,644 shares during the period. Institutional investors and hedge funds own 8.53% of the company’s stock.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Featured Story: Return on Investment (ROI) Defined, Explained

Insider Buying and Selling by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply